Evidence map›Paper›PMID 39529527›Full record

ArticleJournal of the National Cancer Institute. Monographs2024

Impact of single-dose HPV vaccination on HPV 16 and 18 prevalence in South African adolescent girls with and without HIV.

Sinead Delany-Moretlwe, Dorothy A Machalek, Danielle Travill, Kathy Petoumenos, Dorothy C Nyemba, Zizipho Z A Mbulawa, Nontokozo Ndlovu, John M Kaldor, Helen Rees

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute. Monographs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sinead Delany-MoretlweWits RHI, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-0376-1019
Dorothy A MachalekKirby Institute, University of New South Wales, Sydney, Australia.ORCID 0000-0002-4101-8085
Danielle TravillWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Kathy PetoumenosKirby Institute, University of New South Wales, Sydney, Australia.
Dorothy C NyembaWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Zizipho Z A MbulawaNational Health Laboratory Service, Nelson Mandela Academic Hospital, Mthatha, South Africa.
Nontokozo NdlovuWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
John M KaldorKirby Institute, University of New South Wales, Sydney, Australia.ORCID 0000-0002-7639-4355
Helen ReesWits RHI, University of the Witwatersrand, Johannesburg, South Africa.

Funding

Gates Foundation OPP11956557National Health and Medical Research Council of Australia APP1164430
6 · The paper itself

Abstract

backgroundThe World Health Organization has endorsed single-dose human papillomavirus (HPV) vaccination, but data on the impact on HPV prevalence in high HIV burden settings are limited.

methodsA single-dose bivalent HPV vaccine was delivered to adolescent girls in grade 10 in a schools-based campaign in 1 district in South Africa. Impact on HPV 16 and 18 prevalence was evaluated using repeat cross-sectional surveys. A clinic-based survey in girls aged 17-18 years established HPV 16 and 18 prevalence in a prevaccine population (n = 506, including 157 living with HIV) in 2019 and was repeated in the same age group and sites in a single-dose eligible population in 2021 (n = 892, including 117 with HIV). HPV DNA was detected on self-collected vaginal swabs using the Seegene Anyplex II HPV 28. Population impact was estimated overall and by HIV status using prevalence ratios adjusted for differences in sexual behavior between surveys.

resultsSingle-dose vaccination campaign coverage was 72% (4807 of 6673) of eligible girls attending high school (n = 66) in the district. HPV 16 and 18 prevalence was 35% lower in the postvaccine survey overall (adjusted prevalence ratio = 0.65, 95% confidence interval [CI] = 0.51 to 0.83; P < .001) and 37% lower in those living with HIV (adjusted prevalence ratio = 0.63, 95% CI = 0.41 to 0.95; P  = .026). No protective effect was seen for nonvaccine oncogenic HPV types 33, 35, 39, 51, 52, 56, 58, 59, or 68 overall (adjusted prevalence ratio = 1.14, 95% CI = 1.03 to 1.26; P = .011) or in those living with HIV (adjusted prevalence ratio = 1.00, 95% CI = 0.83 to 1.21. P = 0.99).

conclusionThese data provide reassuring evidence of single-dose impact on population-level HPV 16 and 18 prevalence in a South African population, irrespective of HIV status.

Indexed as

HIV InfectionsHuman papillomavirus 16Human papillomavirus 18Papillomavirus InfectionsPapillomavirus VaccinesAdolescentCross-Sectional StudiesFemaleHumansPrevalenceSouth AfricaVaccinationPapillomavirus Vaccines

Identifiers

PMID39529527
PMCPMC11555272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.